Rhenman & Partners Asset Management’s Edwards Lifesciences EW Stock Holding History

Rhenman & Partners Asset Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.1M	Sell	163,000 -30,500	-16%	-$2.51M	1.61%	20
2025 Q4	$16.5M	Buy	193,500 +38,500	+25%	+$3.16M	1.54%	24
2025 Q3	$12.1M	Buy	155,000 +100,000	+182%	+$7.81M	1.33%	31
2025 Q2	$4.3M	Buy	+55,000	New	+$4.1M	0.54%	55
2024 Q3	–	Sell	-97,500	Closed	-$9.01M	–	96
2024 Q2	$9.01M	Buy	+97,500	New	+$8.63M	0.86%	40
2023 Q4	–	Sell	-29,000	Closed	-$2.01M	–	89
2023 Q3	$2.01M	Hold	29,000	–	–	0.22%	72
2023 Q2	$2.74M	Sell	29,000 -41,000	-59%	-$3.56M	0.29%	70
2023 Q1	$5.71M	Sell	70,000 -74,000	-51%	-$5.82M	0.63%	54
2022 Q4	$10.7M	Buy	144,000 +19,000	+15%	+$1.46M	1.12%	33
2022 Q3	$9.05M	Buy	125,000 +80,000	+178%	+$7.7M	0.95%	41
2022 Q2	$4.28M	Sell	45,000 -20,000	-31%	-$2.07M	0.49%	54
2022 Q1	$7.65M	Sell	65,000 -35,000	-35%	-$3.93M	0.76%	48
2021 Q4	$13.1M	Sell	100,000 -5,000	-5%	-$583K	0.87%	43
2021 Q3	$11.9M	Sell	105,000 -5,000	-5%	-$571K	0.83%	48
2021 Q2	$11.4M	Hold	110,000	–	–	0.77%	54
2021 Q1	$9.2M	Sell	110,000 -15,000	-12%	-$1.27M	0.64%	52
2020 Q4	$11.4M	Buy	125,000 +5,000	+4%	+$415K	0.93%	46
2020 Q3	$9.58M	Hold	120,000	–	–	0.85%	45
2020 Q2	$8.29M	Sell	120,000 -51,000	-30%	-$3.62M	0.9%	45
2020 Q1	$10.8M	Buy	171,000 +57,000	+50%	+$4.11M	1.51%	27
2019 Q4	$8.87M	Buy	114,000 +4,245	+4%	+$331K	0.97%	44
2019 Q3	$8.04M	Buy	109,755 +15,000	+16%	+$1.05M	1.01%	40
2019 Q2	$5.83M	Buy	94,755 +15,000	+19%	+$907K	0.64%	58
2019 Q1	$5.09M	Sell	79,755 -120,000	-60%	-$6.85M	0.6%	57
2018 Q4	$10.2M	Sell	199,755 -90,000	-31%	-$4.55M	1.17%	40
2018 Q3	$16.8M	Buy	289,755 +84,663	+41%	+$4.14M	1.68%	26
2018 Q2	$9.95M	Sell	205,092 -45,000	-18%	-$2.1M	1.02%	47
2018 Q1	$11.6M	Buy	250,092 +30,000	+14%	+$1.3M	1.43%	30
2017 Q4	$8.27M	Sell	220,092 -19,908	-8%	-$731K	1.12%	33
2017 Q3	$8.74M	Buy	240,000 +141,000	+142%	+$5.38M	1.12%	34
2017 Q2	$3.9M	Sell	99,000 -81,000	-45%	-$2.96M	0.56%	64
2017 Q1	$5.64M	Sell	180,000 -30,000	-14%	-$939K	0.89%	46
2016 Q4	$6.56M	Buy	210,000 +45,000	+27%	+$1.46M	1.26%	29
2016 Q3	$6.63M	Sell	165,000 -45,000	-21%	-$1.69M	1.05%	36
2016 Q2	$6.98M	Buy	210,000 +45,000	+27%	+$1.54M	1.24%	27
2016 Q1	$4.85M	Buy	165,000 +18,000	+12%	+$497K	0.96%	41
2015 Q4	$3.87M	Sell	147,000 -225,000	-60%	-$5.84M	0.59%	61
2015 Q3	$8.81M	Buy	372,000 +204,000	+121%	+$4.92M	1.41%	30
2015 Q2	$3.99M	Buy	168,000 +54,000	+47%	+$1.22M	0.48%	71
2015 Q1	$2.71M	Hold	114,000	–	–	0.46%	78
2014 Q4	$2.42M	Sell	114,000 -6,000	-5%	-$121K	0.7%	62
2014 Q3	$2.04M	Sell	120,000 -90,000	-43%	-$1.42M	0.6%	64
2014 Q2	$3M	Sell	210,000 -67,122	-24%	-$910K	0.89%	38
2014 Q1	$3.43M	Buy	+277,122	New	+$3.2M	1.03%	32

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Rhenman & Partners Asset Management's EW Position: Q1 2026 in Review

Rhenman & Partners Asset Management reduced its Edwards Lifesciences (EW) stake by 16% in Q1 2026, selling an estimated $2.51M and leaving 163,000 shares worth $13.1M. The position accounts for 1.61% of the portfolio, ranked #20.

Rhenman & Partners Asset Management first reported a position in EW in Q1 2014 and has held it in 44 quarters since. The position peaked at $16.8M in Q3 2018. 1,285 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Rhenman & Partners Asset Management held 163,000 shares of Edwards Lifesciences worth $13.1M as of Q1 2026.
Rhenman & Partners Asset Management sold 30,500 Edwards Lifesciences shares in Q1 2026, an estimated $2.51M.
Edwards Lifesciences made up 1.61% of Rhenman & Partners Asset Management's portfolio in Q1 2026, its #20 holding.
Rhenman & Partners Asset Management first reported a position in Edwards Lifesciences in Q1 2014 and has held it in 44 quarters since.
Rhenman & Partners Asset Management's Edwards Lifesciences position peaked at $16.8M in Q3 2018.
1,285 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.